HADHA and hepatocellular carcinoma: Recent studies have also highlighted the potential of targeting the UBE2O/HADHA axis in the treatment of hepatocellular carcinoma (HCC), the most common primary malignant liver tumor and the sixth highest cause of cancer-related death [71].